Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared

SG&A Spending: Blueprint vs. Catalyst Pharmaceuticals

__timestampBlueprint Medicines CorporationCatalyst Pharmaceuticals, Inc.
Wednesday, January 1, 201478900004473654
Thursday, January 1, 2015144560008597010
Friday, January 1, 2016192180007910260
Sunday, January 1, 2017279860007304399
Monday, January 1, 20184792800015875961
Tuesday, January 1, 20199638800036881187
Wednesday, January 1, 202015774300044233754
Friday, January 1, 202119529300049628000
Saturday, January 1, 202223737400058183000
Sunday, January 1, 2023295141000133710000
Monday, January 1, 2024359272000
Loading chart...

In pursuit of knowledge

SG&A Spending Trends: Blueprint Medicines vs. Catalyst Pharmaceuticals

In the competitive landscape of pharmaceuticals, understanding spending patterns is crucial. Over the past decade, Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Blueprint Medicines saw a staggering increase of over 3,600% in SG&A expenses, peaking at nearly $295 million in 2023. In contrast, Catalyst Pharmaceuticals experienced a more modest rise of approximately 2,900%, reaching $134 million in the same year.

This divergence highlights Blueprint's aggressive expansion strategy, possibly reflecting increased marketing efforts and administrative scaling. Meanwhile, Catalyst's steadier growth suggests a more conservative approach. These spending patterns not only reflect each company's strategic priorities but also offer insights into their market positioning and future growth potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025